ClinicalTrials.gg
TerminatedNCT06714591Updated Sep 24, 2026

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

A Phase 1 interventional study of BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia, sponsored by SystImmune Inc.. Terminated at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by SystImmune Inc. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor prioritization of other development portfolio

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 311 open to participants now, 465 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
646th of 1,907
52 · median 35
Started
2024
with 70 others
Phase 1
772 of 2,137
130 open now
Registered
2,018th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 646th largest by enrollment of the 1,907 interventional ones that give a count, is one of 71 that started in 2024, is one of 772 in phase 1, and was the 2,018th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

311 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

306 more — sign in →

All 311 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

Read the detailed description

BL-M11D1-HM-101 is a multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

This study will be conducted in two parts (dose escalation, and dose finding). Cohort A will be dosed on Days 1, 8,15 of a continuous 28-day treatment cycle. The cohort has different dose groups. Cohort B will be dosed on Days 1, 4, 7 or 8 of a continuous 28-day treatment cycle. The cohorts have different dose groups.

03

Conditions studied

  • Relapsed/Refractory Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed the
  2. Age ≥18 years
  3. Has a of ≥3 months
  4. CD33-positive AML as determined by local pathology review that has failed initial standard of care therapy. Diagnosis of primary AML or AML secondary to myelodysplastic syndromes. Relapsed or refractory status. CD33-positive as confirmed by local flow cytometry or cytology
  5. Has an performance status (ECOG PS) 0 to 2
  6. Toxicity of previous anticancer therapy has returned to Grade ≤1 as defined by V5.0, except for alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2
  7. Has adequate liver and renal function before registration, defined as: a. Hepatic function: Total (TBIL) ≤1.5× (≤3×ULN for subjects with Gilbert's syndrome), (AST) and alanine aminotransferase (ALT) ≤2.5×ULN b. Renal function: ≥50 mL/min (Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration [CKD-Epi], or Modification of Diet in Renal Disease Study [] equations)
  8. Sexually active fertile subjects and their partners must agree to use highly effective methods of during the course of the study and for 7 months after the last dose of study treatment. An additional contraceptive method, such as a barrier method (eg, condom), is recommended
  9. Women of (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating

Exclusion criteria

Exclusion Criteria:

  1. Subjects with acute promyelocytic leukemia (APL) or chronic myelogenous leukemia in blast crisis (CML)
  2. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other anticancer therapy within 2 weeks) prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration, or palliative radiotherapy within 2 weeks prior to the first administration
  3. Subjects with history of severe heart disease, such as symptomatic congestive heart failure (CHF) ≥ Grade 2 ( 5.0), (NYHA) ≥ Grade 2 heart failure, history of transmural myocardial infarction, unstable cardiac arrhythmias or angina pectoris within 6 months before screening
  4. Subjects with prolonged (QTcF >470 msec), complete left bundle branch block, Grade 3 atrioventricular block or a history of additional risk factors for Torsades de Pointes (TdP; eg, heart failure as defined in Exclusion Criterion 3, chronic or recurrent hypokalemia that requires medical intervention, congenital long QT syndrome, family history of long QT syndrome) or any current concomitant medication known to prolong the QT/QTc interval or cause TdP
  5. Active diseases and inflammatory diseases, such as: systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for Type I diabetes, hypothyroidism that can be controlled only by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis)
  6. Subjects with other prior or concurrent except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with as disease-free interval of at least 1 year
  7. Subjects with poorly controlled hypertension or uncontrolled hypertension by two or more antihypertensive drugs (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg)
  8. Subjects with active acute or chronic graft vs. host disease (aGVHD or cGVHD) should be excluded from this study. Subjects with who are receiving treatment with systemic >10 mg/day equivalent of prednisone should also be excluded from the study; however, treatment with low-dose glucocorticoids (≤10 mg/day equivalent of prednisone) is permitted
  9. Subjects currently receiving therapy should be excluded from this study.
  10. Clinical evidence of disseminated intravascular coagulation (DIC). Smoldering low grade DIC is allowed after discussion with the sponsor
  11. Subjects with stroke or (TIA) within 6 months before screening
  12. Subjects with a thromboembolic event (eg, deep vein thrombosis [DVT] or pulmonary embolism [PE]) within 6 months before screening except for those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before screening
  13. Subjects with active central nervous system (CNS) AML will be excluded. A lumbar puncture does not need to be performed unless there is clinical suspicion of CNS involvement per investigator judgment. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS AML is allowed with the approval of the sponsor
  14. Subjects with pre-existing ≥Grade 2 peripheral neuropathy
  15. Subjects with advanced/ lung diseases, such as poorly controlled and asthma, restrictive lung disease, pulmonary hypertension etc.
  16. Subjects who have a history of noninfectious interstitial lung disease (ILD)/ pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  17. Subjects who have a history of anaphylaxis or severe to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-M11D1
  18. Subjects with known infection (HIV Ab positive) Subjects are allowed to participate if all of the following criteria are met: (1) Undetectable HIV RNA and ≥350 cells/μL at screening, (2) No AIDS defining opportunistic infection within 12 months prior to screening, (3) On stable antiretroviral therapy (ART) for at least 4 weeks prior to screening with projected continuation of ART as clinically indicated while on the study
  19. Subjects with active virus (HBV) infection (positive HBsAg test). Subjects with chronic inactive HBV infection are eligible if they meet all of the following criteria:

    1. Have a HBV DNA viral load ≤ 500 IU/mL
    2. Have normal and ALT, OR if liver involvement is present, has AST and ALT \<3 × which are not attributed to HBV infection
    3. on antiviral treatment, as clinically indicated
  20. Subjects with active virus (HCV) infection (HCV antibody positive and HCV-RNA > the lower limit of detection). Subjects with a positive anti-HCV antibody are eligible only if PCR is negative for HCV RNA
  21. Subjects with active or latent tuberculosis
  22. Subjects with active and uncontrolled infections requiring IV antibiotic, antiviral, or antifungal treatment, such as severe pneumonia, bacteremia, sepsis, etc., within 1 week prior to first dose of study treatment. Subjects on stable oral antimicrobials with no clinical or laboratory evidence of active infection are eligible
  23. Received an drug within 2 weeks prior to first dose of study treatment.
  24. Subjects who are pregnant, breastfeeding, or planning to become pregnant during the study
  25. Prior treatment with a topoisomerase inhibitor-based antibody-drug conjugate (ADC.)
  26. Previous history of significant gastrointestinal conditions, including Grade 3 or higher diarrhea, colitis, gastrointestinal bleeding and history of major gastrointestinal surgeries

28. Progressed on more than 2 different lines of systemic cytotoxic therapies; patients with 3 prior lines of systemic cytotoxic therapy or with prior stem cell transplant may be enrolled upon consultation and approval from the sponsor

Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Experimental: Cohort A BL-M11D1 administered Days 1, 8 and 15 in 28-day cycle

    Cohort A: BL-M11D1 will be administered on Days 1, 8 and 15 by intravenous infusion every 28 days.

    Drug: BL-M11D1

  • Experimental
    Experimental: Cohort B BL-M11D1 administered Days 1, 4 7 or 8 in 28-day cycle

    Cohort B: BL-M11D1 will be administered on Days 1,4, 7 or 8 by intravenous infusion every 28 days.

    Drug: BL-M11D1

Interventions

  • The study includes 2 parts: Part 1 Dose escalation and Dose Finding

06

What researchers measure

Primary outcomes

  1. Participants with dose-limiting toxicities

    DLTs are defined as any of the following events that are not clearly due to the underlying disease, disease progression, or extraneous causes: * Any treatment-emergent adverse event (TEAE) of ≥ Grade 3 except those due to disease progression or extraneous cause * Any TEAE that leads to dose reduction or withdrawal Nonhematologic toxicities * Death * Hy's law cases * Grade ≥3 nonhematologic toxicities (with exceptions) Hematologic toxicity * Grade 4 thrombocytopenia or neutropenia lasting \>42 days in the absence of persistent leukemia * Grade ≥3 platelet count decreased with clinically significant hemorrhage

    Time frame: 1 Year

  2. Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)

    Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)

    Time frame: 1 Year

  3. To determine the minimum safe and effective dose (MSED), maximum tolerated dose (MTD) if reached, and maximum administered dose (MAD) of BL-M11D1 in AML

    Determine the highest BL-M11D1 dose level at which ≤33% subjects experience a DLT during the DLT evaluation period and highest BL-M11D1 dose administered in the event and MTD cannot be defined.

    Time frame: 1 Year

Secondary outcomes

  1. Cmax of BL-M11D1

    Calculate maximum (peak) observed concentration of BL-M11D1

    Time frame: 1 Year

  2. Tmax of BL-M11D1

    Calculate time of maximum observed concentration of BL-M1D1

    Time frame: 1 Year

  3. Tmax of free payload ED-04

    Calculate time of maximum observed concentration of free payload ED-04

    Time frame: 1 Year

  4. Cmax of free payload ED-04

    Calculate maximum (peak) observed concentration of free payload ED-04

    Time frame: 1 Year

  5. AUC(0-8) of BL-M11D1

    Calculate area under the serum concentration-time curve of BL-M11D1 from time 0 to 8 hours

    Time frame: 1 Year

  6. AUC(0-8) of free payload ED-04

    Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours

    Time frame: 1 Year

  7. AUC(last) of BL-BM11D1

    Calculate area under the serum concentration-time curve up of BL-M11D1 to the last quantifiable time

    Time frame: 1 Year

  8. AUC(last) of free payload ED-04

    Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time

    Time frame: 1 Year

  9. Tmax of anti-CD33 antibody

    Calculate time of maximum observed concentration of anti-CD33 antibody

    Time frame: 1 Year

  10. AUC (0-8) of anti-CD33 antibodies

    Calculate area under the serum concentration-time curve of anti-CD33 antibodies from time 0 to 8 hours

    Time frame: 1 Year

  11. AUC (last) anti-CD33 antibodies

    Calculate area under the serum concentration-time curve up of anti-CD33 antibodies to the last quantifiable time

    Time frame: 1 Year

  12. Overall Response Rate (ORR)

    To assess the clinical efficacy of BL-M11D1 as measured by ORR using RECIST criteria v 1.1

    Time frame: 1 Year

  13. Duration of response (DOR)

    To access the clinical efficacy of BL-M11D1 as measured by DOR using RECIST criteria 1.1

    Time frame: 1 Year

  14. Complete Remission (CR)

    To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

    Time frame: 1 Year

  15. CR with partial hematologic recovery (CRh)

    To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

    Time frame: 1 Year

  16. CR with incomplete hematologic recovery (CRi)

    To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

    Time frame: 1 Year

  17. CR/CRi, CRs with or without measurable residual disease (MRD)

    To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

    Time frame: 1 Year

  18. morphologic leukemia-free state (MLFS)

    To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

    Time frame: 1 Year

  19. partial remission (PR)

    To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

    Time frame: 1 Year

07

Study locations

18 sites
  • City of Hope
    Duarte, California 91010, United States
  • UCLA Ronald Reagan Medical Center
    Los Angeles, California 90095, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut 06511, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21287, United States
  • START Midwest/The Cancer and Hematology Center
    Grand Rapids, Michigan 49546, United States
  • John Theurer Cancer Center-Hackensack
    Hackensack, New Jersey 07601, United States
  • Oncology Hematology Care Clinical Trials, LLC
    Cincinnati, Ohio 45236, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • WVCI Oncology Associates of Oregon
    Eugene, Oregon 24224, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Temple Health Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • SCRI -TriStar BMT
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Sep 2026, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 3, 2024
StartActual
Dec 19, 2024
Primary completionActual
Sep 16, 2026
CompletionActual
Sep 16, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06714591
Lead sponsor
SystImmune Inc.
Responsible party
Sponsor
First posted
Dec 3, 2024
Start date
Dec 19, 2024
Primary completion
Sep 16, 2026
Completion
Sep 16, 2026
Last update
Sep 24, 2026

Study contacts

Olu Lawson
study director · SystImmune Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD33 Antibody-drug Conjugate BL-M11D1

Start the discussion